The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia
(Efficace F et al. Ann Hematol, November 2015)
(epub ahead of print) 

Association of promoter polymorphisms of Fas-FasL genes with development of chronic myeloid leukemia
(Edathara PM et al. Tumour Biol, November 2015)
(epub ahead of print)

Incidence and management of myelosuppression in patients with chronic-and accelerated-phase chronic myeloid leukemia treated with oacetaxine mepesuccinate
(Akard L et al. Leuk Lymphoma, October 2015) 
(epub ahead of print)

Discovery of survival factors for primitive chronic myeloid leukemia cells using induced pluripotent stem cells
(Suknuntha K et al Stem Cell Res, October 2015) 
(epub ahead of print)

Accelerated phase chronic myeloid leukemia evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase
(Furtado VF. et al. Bras Heamtol Hemoter, September/October 2015) 

Association of vascular endothelial growth factor A (VEGFA) and its receptor (VEGFR2) gene polymorphisms with risk of chronic myeloid leukemia and influence on clinical outcome
(Lakkireddy S et al. Mol Diagn Ther, October 2015)
(epub ahead of print)

Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia
(Bruzzoni-Giovanelli H et al. Oncotarget,
October 2015)

(Crivellaro S et al. Oncotarget, September 2015)

Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program - Lessons learned from providing access to breakthrough targeted oncology treatment in low- and middle-income countries
(Garcia-Gonzalez P et al. J of Global Oncology, Sept 2015)
(epub ahead of print)

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcr-2 or Bcr Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
(Carter BZ et al. Oncotarget, September 2015) 
(epub ahead of print) 

The impact of dasatinib on pregnancy outcomes
(Cortes JE et al. Am J Hematol, Sept 2015)
(epub ahead of print) 

Erosion of the chronic myeloid leukemia stem cell pool by PPARy agonists
(Prost S et al. Nature, September 2015)
(epub ahead of print)

Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
(Sanford D. et al. Haematologica, September 2015) 

(epub ahead of print) 

Implication of the autologous immune system in BCR-ABL transcript variations in chronic myelogneous leukemia patients treated with imatinib
(Clapp GD et al. Cancer Res, September 2015)
(epub ahead of print)

Polycomb genes are associated with response to imatinib in chronic myeloid leukemia
(Crea F et al. Epigenomics, September 2015) 
(epub ahead of print)

BCR-ABl mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact of survival
(Pagnano KB et al on behalf of Latin American leukemia Net. Cancer Invest, August 2015Cancer Invest, August 2015)
(epub ahead of print)

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors
(Wang W et al. Blood, August 2014)
(epub ahead of print)

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib
(Shah NP et al. Am J Hematol, August 2015) 
(epub ahead of print)

miRNAs as Biomarkers in chronic myelogenous leukemia

(Kotagama K et al. Drug Dev Res, August 2015)
(epub ahead of print)

Comparison of Dasatinib, Nilotinib and Imatinib in the treatment of chronic myeloid leukemia
(Ciargia R. et al. J Cell Physiol, Aug 2015) 
(epub ahead of print)

Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
(Huang et al. Sci Rep, August 2015)

Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase myeloid leukemia. A patient-based survey on 1133 patients
(Breccia M et al. Leuk Res, July 2015)
(epub ahead of print)

A longitudinal evaluation of performence of automated BCR-ABL1 quantification using cartridge-based detection system
(Enjeti A et al. Pathology, July 2015) 
(epub ahead of print)

MicroRNA-320a acts as a tumor suppressor by targeting BCR/ABL oncogene in chronic myeloid leukemia
(Xishan Z. et al. Sci Rep, July 2015)

Tyrosine kinase inhibitor induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling
(Riether C. et al. Sci Transl Med, July 2015)

ß-Catenin is required for intrinsic but not extrinsix BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
(Eiring AM. Leukemia, July 2015)
(epub ahead of print)

A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits
(Nakamae H. et al. Int J Hematol, July 2015)

Sensitive replicate RT-qPCR of BCR-ABL show deep molecular response in long term post allogeneic SCT CML patients
(Koren-Michowitz M. et al. Biol Blood Marrow Transplant, July 2015)
(epub ahead of print)  

Detection of BCR-ABL T315I mutation by peptide nucleic directed PCR clamping and by peptide nucleic acid FISH
(Rosso V. et al. Biomark Res., July 2015)
(epub ahead of print)  

BCR-ABL 1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR
(Zagaria A et al. Virchows Arch, July 2015)
(epub ahead of print)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
(Mancini M. et al. PLoS One, July 2015)

Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats
(Tauer JT et al. PLoS One, June 2015)

The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia
(Dkhissi F. et al. Exp Hematol, June 2015)
(epub ahead of print)

Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
(Castagnetti F. et al. Leukemia, June 2015) 
(epub ahead of print) 

Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia
(Lin HX et al. Eur J Haematol, June 2015)

Expression of the ETS transcription factor GABPa is positively correlated to the BCR-ABL1 ration in CML patients and affects imatinib sensitivity in vitro
(Manukjan G et al. Exp Hematol, June 2015)
(epub ahead of print)

Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 Fusion Type CML under imatinib therapy
(Haaß W. et al. PLoS one, June 2015)

Epigenetic inactivation of DLX4 is associated with disease progression in chronic myeloid leukemia
(Zhoug JD et al. Biochem Biophys Res Comm, June 2015) 
(epub ahead of print)

Reconsideration of BCR-ABL protein flow cytomatic immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
(Kelani R et al. Int. J Lab Hematol, June 2015)  
(epub ahead of print)

Mai 2015

Treatment milestones in chronic myelogenous leukemia: Stay the course or change therapy?
(Radich, JP. J Natl Compr Canc Netw, May 2015)

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia
(Gioia et al. J Pathol, May 2015) 
(epub ahead of print)

Diagnosing and managing advanced chronic myeloid leukemia
(Deininger MW. Am Soc Clin Oncol Educ Book, May 2015)

1,3 butadiene, CML and the t(9:22) translocation: A reality check
(Albertini RJ et al. Chem Biol Interact, May 2015
(epub ahead of print)

Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
(Latagliata R. et al. Leuk Lymphoma, May 2015) 
(epub ahead of print)

Dissecting the role of aberrant DNA methylation in human leukaemia
(Amabile G. et al. Nat. Comm, May 2015)

Management of advanced-phase chronic myeloid leukemia
(De Filipp Z et al. Curr Hematol Malig Rep, May 2015)
(epub ahead of print)

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity
(Pietarinen PO et al. Blood Cancer, May 2015)

Final analysis of the efficacy and safety of omacetacine mepesuccinate in patients with chronic- or accelerated phase chronic myloid leukemia: Results with 24 months of follow-up
(Cortes et al. Cancer, January 2015) 
(epub ahead of print) 

April 2015

Cardiovascular and pulmonary adverse events in patients treated with BCR-AB inhibitors: Data from the FDA adverse event reporting system
(Cortes J et al. Am J Hematol, April 2015)

Milestones and Monitoring
(Morotti A et al. Curr Hematol Malig Rep, April 2015) 
(epub ahead of print)

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML-Study IV
(Saußele S et al. Blood, April 2015) (epub ahead of print)

Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis
(Wang W et al. J Hematol Oncol, April 2015) 

A phase I study of Danusertib (PHA 739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and philadelphia chromosome-positive acute lymphblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy
(Borthakur G et al. Haematologica, April 2015) 
(epub ahead of print) 

Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation
(Konuma T. et al. Leuk Lymphoma, April 2015) 
(epub ahead of print)

Coexpression of hyperactivated AKT1 with additional genes activated in leukemia drives hematopoietic progenitor cells to cell cycle block and apostosis

(Tang Y et al. Exp Hematol, April 2015)

A review of the European LeukemiaNet recommendations
(Baccarani M. et al. Ann Hematol, April 2015)

Detection of small abnormal b-lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR-ABL1+: incidence, phenotypic features, and clinical implications

(Vrotsos E et al. Cytometry B Clin Cytom, April 2015) 
(epub ahead of print)

Discontinuation of tyrosine kinase inhibitor therapy in CML
(Mahon MX. Ann Hematol, April 2015)

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization
(Cross NC et al. Ann Hematol, April 2015)

Causes of resistance and treatment choices in second- and third-line treatment in chronic meylogenous leukemia patients
(Hochhaus A et al. Ann Hematol, April 2015)

Response related predictors of survival in CML
(Hanfstein B. et al. Ann Hematol, April 2015) 

The choice of first-line chronic myelogenous leukemia treatment
(Fava C et al. Ann Hematol, April 2015) 

BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts
(Li Q et al. Cancer Gene Ther, April 2015) 
(epub ahead of print)

Chronic Myeloid Leukaemia
(Apperley JF. Lancet Apr, 2014)  

Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase
(Fallah P et al. Int J Lab Hematol, April 2015) 

March 2015

Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: An evolving treatment paradigm

(Jabbour et al. Clin Lymphoma Myeloma Leuk, March 2015)
(epub ahead of print)

Update on emerging treatments for chronic myeloid leukemia
(Fava C et al. Expert Opin Emerg Drugs, March 2015)
(epub ahead of print)

Secondary mutations as mediators of resistance to targeted therapy in leukemias
(Daver N. et al. Blood, March 2015)
(epub ahead of print)

Second malignancies following treatment of chronic myeloid leukemia in the tyrosine kinase inhibitor era
(Gunnarson N et al. Br J Haematol, March 2015) 
(epub ahead of print)

Phase 3 study of nilotinib vs imatinib in chinese patients with newly diagnosed CML in chronic phase: ENESTchina
(Wang J et al. Blood, March 2015)
(epub ahead of print)

February 2015

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid Leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors
(Ursan ID et al. J Mang Care Spec Pharm, February 2015)

Prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet2013 criteria 
(Murai K et al. Eur J Haematol, February 2015) 
(epub ahead of print)

Laboratory recommentations for scoring deep molecular responses following treatment for chronic myeloid leukemia
(Cross NC et al. Leukemia, February 2015) 
(epub ahead of print)

The role of observational studies in optimizing the clinical management of chronic myeloid leukemia
(Mauro MJ et al. Ther Adv Hematol, 
February 2015)

Morgana acts as an oncosuppressor in chronic myeloid leukemia
(Di Savina A et al. Blood, February 2015)  
(epub ahead of print)

Generic imatinib in the treatment of chronic myeloid leukemia: The Carrahpasa experience
(Eskazan AE et al. J Oncol Pharm Pract, 
February 2015)

Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid Leukemia: A meta-analysis of clinical trials of tyrosine kinase inhibitors
(Ursan ID et al. J Mang Care Spec Pharm, 
February 2015)

Analyzing molecular response in chronic myleoid leukemia clinical trials: Pitfalls and golden rules
(Guilhot J et al. Cancer, February 2015) 

Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
(Rochau et al. Leuk Lymphoma, January 2015)  
(epub ahead of print)

Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia
(Kaeda J et al. Leuk Lymphoma, Januar 2015) 
(epub ahead of print)

Cardiovascular and pulmonary events in patients treated with BCR-ABL inhibitors: Data from the FDA adverse events reporting system
(Cortes J et al. Am J Hematol, January, 2015) 
(epub ahead of print)

BCR-ABL inactivates cytosolic PTEN through casein kinase II mediated tail phosphorylation 
(Morotti A et al. Cell Cycle, January 2015) 
(epub ahead of print)

Do we need more drugs for chronic myeloid leukemia?
(Holyoake T et al, Immunol. Rev, January 2015)

Patients with Philadelphina-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominately relapse with the same mutation
(Egan DG et al. Biol Blood Marrow Transpl, January 2015)

Real-life comparison of severe vascular events and other non-hematological complications in chronic myeloid leukemia patients undergoing second line nilotinib or dasatinib treatment
(Gora-Tybor J et al. Leuk Lymphoma, January 2015) 
(epub ahead of print)

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukemia patients in chronic phase 
(Alonso-Dominguez JM et al. Am J Hematol, January 2015) 

ELN 2013 response status criteria: Relevance for a novo imatinib chronic phase myeloid leukemia patients?
(Etienne G. et al. Am J Hematol, January 2015)

Disruption of IKAROS in primitive chronic phase CML mimics myeloid disease progression                       (Bear PA et al. Blood, January 2015) 

The BCR-ABL inhibitor ponatinib inhibits placelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
(Loren CP et al. Thromb Res, January 2015)